Edward J. Rapp - 30 Sep 2026 Form 4 Insider Report for AbbVie Inc. (ABBV)

Reporting relationship: Director
Issuer ticker: ABBV
Reported as of: 30 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Oct 2026, 17:00:07 UTC
Prior SEC filing: 14 Jul 2026
Next SEC filing: 13 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ T.O. Odutayo, Attorney-in-Fact for Edward J. Rapp

Filing notes and source

Key filing fact

Edward J. Rapp filed Form 4 for AbbVie Inc. (ABBV) on 02 Oct 2026.

Key facts

This page summarizes Edward J. Rapp's Form 4 filing for AbbVie Inc. (ABBV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Oct 2026, 17:00.

Change

Previous filing in this sequence was filed on 14 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001171780 Primary reporting owner

RAPP EDWARD J

Relationship: Director
Address: 1 N. WAUKEGAN ROAD, NORTH CHICAGO
Signature: /s/ T.O. Odutayo, Attorney-in-Fact for Edward J. Rapp
Signature date: 02 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABBV transaction Derivative

Stock Equivalent Units

Award

Transaction value
Shares: +129
Change %: +0.44%
Price: $261.59^*
Shares after: 29,568
Date: 30 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 129
Exercise price: $261.59
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Director fees credited to a stock equivalent unit account under the director's grantor trust are distributed over a period equal to the director's years of board service, generally commencing at the later of age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

Footnote F2

Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.